DXCM peers and competitors
DexCom, Inc. · end-of-day data as of Oct 16, 2026
DexCom, Inc.
$86.04+20.3%
Buy · 29 analystsPT $96.98 +12.7%
DXCM’s peers by industry and size include Abbott Laboratories (ABT), Medtronic Plc (MDT) and Stryker (SYK). Among these 12 companies DXCM ranks 8th by market cap ($32.47B); its P/E of 34.0 compares with a median of 25.6 for its peers.
Peers by industry and size
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $104.89 | +0.2% | -17.7% | +16.6% | 33.7 | $181B | |
| 2 |  | $94.75 | -0.7% | -7.1% | +4.0% | 23.3 | $121B | |
| 3 |  | $294.66 | +0.5% | -23.3% | +23.9% | 30.5 | $113B | |
| 4 |  | $44.39 | +0.6% | -57.7% | +50.1% | 18.0 | $64.33B | |
| 5 |  | $86.60 | -1.7% | -9.0% | +15.2% | 49.8 | $49.9B | |
| 6 |  | $79.38 | +1.2% | -45.2% | +24.2% | 13.1 | $32.78B | |
| 7 |  | $1,622.29 | -1.0% | -1.0% | -7.3% | 36.5 | $32.51B | |
| 8 | | $86.04 | -1.9% | -6.8% | +12.7% | 34.0 | $32.47B | |
| 9 |  | $69.57 | -1.1% | -21.0% | +20.2% | 20.2 | $31.42B | |
| 10 |  | $94.98 | +0.6% | -7.7% | +9.0% | 23.1 | $18.12B | |
| 11 |  | $147.31 | -1.4% | -25.4% | +35.1% | 25.6 | $10.46B | |
| 12 |  | $141.10 | +1.7% | -59.3% | +32.3% | 26.4 | $9.79B |
Data as of Oct 16, 2026 close.